CureVac GmbH, a pioneer in RNA technology, is set to work with Boehringer Ingelheim on two new oncology projects that will seek to improve outcomes for patients with non-small lung cancer by leveraging existing treatments with a cancer vaccine. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News
